Correlation between microstructure and bioequivalence in Anti–HIV Drug Efavirenz.
Fandaruff C, Segatto Silva MA,  et al
Eur J Pharm Biopharm. 2015 Feb 3.
Abstract

Molecularly imprinted nanoparticles prepared by miniemulsion polymerization as a sorbent for selective extraction and purification of efavirenz from human serum and urine.
Pourfarzib M, Shekarchi M, Rastegar H,  et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 1;974:1-8.
Abstract

Protein-free Efavirenz is Equivalent in Cerebrospinal Fluid & Blood Plasma: Applying the Law of Mass Action to Predict Protein-Free Drug Concentration
Avery LB, Sacktor N, McArthur JC, Hendrix CW. 
Antimicrob Agents Chemother. 2013 Jan 7.
Abstract

Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.
Metzger IF, Quigg TC, Epstein N, et al
Curr Ther Res Clin Exp. 2014 Sep 27;76:64-9.
Abstract

Efavirenz Induces Neuronal Autophagy and Mitochondrial Alterations.
Purnell PR, Fox HS.
J Pharmacol Exp Ther. 2014 Aug 26.
Abstract

A WEEK-IN-REVEW FEATURED REPORT
Differential Subcutaneous Adipose Tissue Gene Expression Pattern with Efavirenz or Lopinavir/ritonavir in Antiretroviral-Naïve Patients: A Randomized Clinical Trial.
Egaña-Gorroño L, Martínez E, Domingo P, et al
Antimicrob Agents Chemother. 2014 Aug 25
Abstract

A WEEK-IN REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) – Agents That Concern Prescribers and Patients:
A Feasibility Study and Call for a Trial.
Achhra AC, Boyd MA, Law MG, et al
PLoS One. 2014 Jun 26;9(6):e99530.
Paper

FULL-TEXT ARTICLE
Efavirenz Promotes β-Secretase Expression and Increased Aβ1-40,42 via Oxidative Stress and Reduced Microglial Phagocytosis: Implications for HIV Associated Neurocognitive Disorders (HAND).
Brown LA, Jin J, Ferrell D, et al
PLoS One. 2014 Apr 23;9(4):e95500.
Paper

A WEEK-IN REVIEW FEATURED REPORT
Has the time come to abandon efavirenz for first-line antiretroviral therapy?
Raffi F, Pozniak AL, Wainberg MA.
J Antimicrob Chemother. 2014 Mar 5.
Abstract

The phenolic metabolites of the anti-HIV drug efavirenz: Evidence for distinct reactivities upon oxidation with Frémy’s salt.
Harjivan SG, Wanke R, Ferreira da Silva JL, et al
Eur J Med Chem. 2013 Dec 31;74C:7-11
Abstract

Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method.
Tshweu L, Katata L, Kalombo L, Chiappetta DA,  et al
Nanomedicine (Lond). 2013 Dec 23
Abstract

Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism.
Sukasem C, Manosuthi W, Koomdee N, et al
Infection. 2013 Nov 30.
Abstract

Factors associated with remaining on initial randomized efavirenz-containing regimens.
Smurzynski M, Wu K, Schouten JT,  et al 
AIDS. 2013 Jul 31;27(12):1887-97.
Abstract

Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.
Avery LB, Sacktor N, McArthur JC, Hendrix CW. 
Antimicrob Agents Chemother. 2013 Aug;57(8):4095
Abstract